The Acute Respiratory Distress Syndrome: Role of Nutritional Modulation of Inflammation Through Dietary Lipids

Abstract

The acute respiratory distress syndrome (ARDS) is the most serious form of acute hypoxic respiratory failure. ARDS represents the expression of an acute, diffuse, inflammatory process in the lungs consequent to a variety of infectious and noninfectious conditions. It is characterized pathologically by damage to pulmonary epithelial and endothelial cells, with subsequent alveolar-capillary leak and exudative pulmonary edema. The main clinical features of ARDS include rapid onset of dyspnea, severe defects in gas exchange, and imaging studies demonstrating diffuse pulmonary infiltrates. The role of nutrition in the management of ARDS has traditionally been supportive. Recent research has demonstrated the potential of certain dietary oils (eg, fish oil, borage oil) to modulate pulmonary inflammation, thereby improving lung compliance and oxygenation, and reducing time on mechanical ventilation. This article reviews the alterations in the immune response that underlie ARDS, discusses the physiology of dietary oils as immunonutrients, summarizes animal and human studies that explore the therapeutic effects of dietary oils, and provides clinical recommendations for their use.

Get full access to this article

View all access options for this article.

References

Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967 ;2:319– 323.

Bernard GR, Artigas A, Krigham KL, et al. The American-European Consensus Conference of ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818– 824.

Flaaten H, Gjerde S, Guttormson AB, et al. Outcome after acute respiratory failure is more dependent on dysfunction in other vital organs than on the severity of the respiratory failure. Crit Care. 2003;7:R72– R77.

Cordingley JJ, Keogh BF. The pulmonary physician in critical care 8: ventilatory management of ALI/ARDS. Thorax. 2002 ;57:729– 734.

Cranshaw J, Griffiths MJD, Evans TW. The pulmonary physician in critical care 9: non-ventilatory strategies in ARDS. Thorax. 2002;57:823– 829.

Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med. 2001;163:316– 321.

Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 ;340:448– 454.

Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 ;101:1644– 1655.

Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med. 1999; 160(5 pt 2):S5– S11.

10.

Bhatia M, Moochhala SJ. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 2004;202:145– 156.

11.

Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. Immunol Res. 2001 ;24:273– 287.

12.

Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock. 2001;16:83– 96.

13.

Cavaillon JM, Adib-Conquy M, Cloez-Tayarani I, Fitting C. Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: a review. J Endotoxn Res. 2001;7:85– 93.

14.

Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997 ;112:235– 243.

15.

Ronco C, Bonello M, Bordoni V, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif. 2004 ;22:164– 174.

16.

Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schuttler J. Coincidence of pro- and anti-inflammatory response in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002 ;30:1015– 1023.

17.

Standen J, Bihari D. Immunonutrition: an update. Curr Opin Clin Nutr Metab Care. 2000 ;3:149– 157.

18.

Grimm H, Mayer K, Mayser P, Eigenbrodt E. Regulatory potential of n-3 fatty acids in immunological and inflammatory processes. Br J Nutr. 2002;87(Suppl 1):S59– S67.

19.

Von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids. 2001 ; 36(Suppl):S99– S102.

20.

Horrobin DF. Fatty acid metabolism in health and disease: the role of Δ-6 desaturase. Am J Clin Nutr. 1993 ;57(Suppl):732S– 737S.

21.

Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997 ;66:649– 659.

22.

Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med. 2000 ;28(Suppl):N27– N36.

23.

Anderson BO, Moore EE, Banerjee A. Phospholipase A₂ regulates critical inflammatory mediators of multiple organ failure. J Surg Res. 1994 ;56:199– 205.

24.

Trebble TM, Wootton SA, Miles EA, et al. Prostaglandin E₂ production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. Am J Clin Nutr. 2003;78:376– 382.

25.

Simopoulos AP. The importance of the ratio of ω-6/ω-3 essential fatty acids. Biomed Pharmacother. 2002 ;56:365– 379.

26.

Spielmann D, Bracco U, Traitler H, et al. Alternative lipids to usual omega 6 PUFAS: γ-linolenic acid, α-linolenic acid, stearidonic acid, EPA, etc. JPEN J Parenter Enteral Nutr. 1988; 12(Suppl):111S– 123S.

27.

Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Nutr. 1999 ;70(Suppl):560S– 569S.

28.

Palombo JD, DeMichele SJ, Boyce PJ, Noursalehi M, Forse RA, Bistrian BR. Metabolism of dietary α-linolenic acid vs. eicosapentaenoic acid in rat immune cell phospholipids during endotoxemia. Lipids. 1998;33:1099– 1105.

29.

Grimble RF. Dietary lipids and the inflammatory response. Proc Nutr Soc. 1998 ;57:535– 542.

30.

Graber R, Rumida C, Nunez EA. Fatty acids and cell signal transduction. J Lipid Mediat Cell Sig. 1994 ;9:91– 116.

31.

Lokesh BR, German B, Kinsella JE. Differential effects of docosahexaenoic acid and eicosapentaenoic acid on suppression of lipoxygenase pathway in peritoneal macrophages. Biochem Biophys Acta. 1988;958:99– 107.

32.

Lokesh BR, Kinsella JE. Modulation of prostaglandin synthesis in mouse peritoneal macrophages by enrichment of lipids with either eicosapentaenoic or docosahexaenoic acids in vitro. Immunobiology. 1987 ;175:406– 419.

33.

Barre DE. Potential of evening primrose, borage, black currant, and fungal oils in human health. Annals Nutr Metab. 2001 ;45:47– 57.

34.

Fan YY, Chapkin RS. Importance of dietary γ-linolenic acid in human health and nutrition. J Nutr. 1998 ;128:1411– 1414.

35.

Garg ML, Thomson AB, Clandinin MT. Effect of dietary cholesterol and/or ω 3 fatty acids on lipid composition and Δ-5 desaturase activity of rat liver microsomes. J Nutr. 1988 ;118:661– 668.

36.

Chapkin RS, Miller CC, Somers SD, Erickson KL. Ability of 15-hydroxyeicosatrienoic acid (15-OH-20:3) to modulate macrophage arachidonic acid metabolism. Biochem Biophys Res Commun. 1988 ;153:799– 804.

37.

de La Puerta Vazquez R, Martinez-Dominguez E, Sanchez Perona J, Ruiz-Gutierrez V. Effects of different dietary oils on inflammatory mediator generation and fatty acid composition in rat neutrophils. Metabolism. 2004 ;54:59– 65.

38.

Murray MJ, Kumar M, Gregory TJ, Banks PL, Tazelaar HD, DeMichele SJ. Select dietary fatty acids attenuate cardiopulmonary dysfunction during acute lung injury in pigs. Am J Physiol. 1995 ;269:H2090– H2099.

39.

Mancuso P, Whelan J, DeMichele SJ, Snider CC, Guszcza JA, Karlstad MD. Dietary fish oil and fish and borage oil suppress intrapulmonary proinflammatory eicosanoid biosynthesis and attenuate pulmonary neutrophil accumulation in endotoxic rats. Crit Care Med. 1997 ;25:198– 206.

40.

Mancuso P, Whelan J, DeMichele SJ, et al. Effects of eicosapentaenoic and gamma-linolenic acid on lung permeability and alveolar macrophage eicosanoid synthesis in endotoxic rats. Crit Care Med. 1997;25:523– 532.

41.

Fisher M, Levine PH, Weiner BH, et al. Dietary n-3 fatty acid supplementation reduces superoxide production and chemiluminescence in a monocyte-enriched preparation of leukocytes. Am J Clin Nutr. 1990;51:804– 808.

42.

D'Ambola JB, Aeberhard EE, Trang N, Gaffar S, Barrett CT, Sherman MP. Effect of dietary (n-3) and (n-6) fatty acids on in vivo pulmonary bacterial clearance by neonatal rabbits. J Nutr. 1991 ;121:1262– 1269.

43.

Palombo JD, DeMichele SJ, Boyce PJ, et al. Effect of short-term enteral feeding with eicosapentaenoic and γ-linolenic acids on alveolar macrophage eicosanoid synthesis and bactericidal function in rats. Crit Care Med. 1999 ;27:1908– 1915.

44.

Gadek JE, De-Michele SJ, Karlstad MD, et al. Effect of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med. 1999;27:1409– 1420.

45.

Fein AM, Calalang-Colucci MG. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Crit Care Clin. 2000;16:289– 317.

46.

Pacht ER, DeMichele SJ, Nelson JL, Hart J, Wennberg AK, Gadek JE. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med. 2003;31:491– 500.

47.

Gillis RC, Daley BJ, Enderson BL, Karlstad MD. Eicosapentaenoic acid and γ-linolenic acid induce apoptosis in HL-60 cells. J Surg Res. 2002;107:145– 153.

48.

Tehila M, Gibstein L, Gordgi D, Cohen JD, Shapira M, Singer P. Enteral fish oil, borage oil and antioxidants in patients with acute lung injury (ALI) [abstract]. Clin Nutr. 2003 ;22(Suppl 1):S20 .

49.

Mayer K, Gokorsch S, Fegbeutel C, et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003 ;167:1321– 1328.

50.

Grimble RF, Howell WM, O'Reilly G, et al. The ability of fish oil to suppress tumor necrosis factor α production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor α production. Am J Clin Nutr. 2002;76:454– 459.

51.

Morlion BJ, Torwesten E, Wrenger K, Puchstein C, Furst P. What is the optimum ω-3 to ω-6 fatty acid (FA) ratio of parenteral lipid emulsions in postoperative trauma? [abstract] Clin Nutr. 1997; 16(Suppl 2):49 .

52.

Quartin AA, Schein RMH. Acute lung injury: is the intensive care unit the tip of the iceberg? Crit Care Med. 2003 ;31:1860– 1861.

53.

Suchner U, Heyland DK, Peter K. Immune-modulatory actions of arginine in the critically ill. Br J Nutr. 2002 ;87(Suppl 1):S121– S132.

54.

Bertolini G, Iapichino G, Radrizzani D, et al. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med. 2003;29:834– 840.

55.

Tu W, Satoi S, Zhang Z, et al. Hepatocellular dysfunction induced by nitric oxide production in hepatocytes isolated from rats with sepsis. Shock. 2003;19:373– 377.

56.

Bansal V, Ochoa JB. Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care. 2003 ;6:223– 228.

57.

Moore FA. Caution: use fat emulsions judiciously in intensive care patients. Crit Care Med. 2001 ;29:1644– 1645.

58.

Lekka ME, Liokatis S, Nathanail C, Galani V, Nakos G. The impact of intravenous fat emulsion administration in acute lung injury. Am J Respir Crit Care Med. 2004 ;169:638– 644.

59.

Waitzberg DL, Lotierzo PH, Logullo AF, Torrinhas RSM, Pereira CCA, Meier R. Parenteral lipid emulsions and phagocytic systems. Br J Nutr. 2002;87(Suppl 1)S49– S57.

60.

Furukawa K, Yamamori H, Takagi K, et al. Influences of soybean oil emulsion on stress response and cell-mediated immune function in moderately or severely stressed patients. Nutrition. 2002 ; 18:235– 240.

61.

Suchner U, Katz DP, Furst P, et al. Effects of intravenous fat emulsions on lung function in patients with acute respiratory distress syndrome or sepsis. Crit Care Med. 2001 ;29:1569– 1574.

62.

Masclans JR, Iglesia R, Bermejo B, Pico M, Rodriguez-Roisin R, Planas M. Gas exchange and pulmonary haemodynamic responses to fat emulsions in acute respiratory distress syndrome. Intensive Care Med. 1998;24:918– 923.

63.

Faucher M, Bregeon F, Gainnier M, Thirion X, Auffray JP, Papazian L. Cardiopulmonary effects of lipid emulsions in patients with ARDS. Chest. 2003;124:285– 291.

64.

Carpentier YA, Simoens C, Siderova V, et al. Recent developments in lipid emulsions: relevance to intensive care. Nutrition. 1997 ;13(Suppl):73S– 78S.

65.

Planas M, Porta I, Sagrista ML, Mora M, Padro JB, Pico M. Fatty acid composition of platelet membrane lipids after administration of two different fat emulsions in critically ill patients. Intensive Care Med. 1999;25:395– 398.

66.

Granato D, Blum S, Rossle C, Le Boucher J, Malnoe A, Dutot G. Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. JPEN J Parenter Enteral Nutr. 2000;24:1113– 1118.

67.

Lindgren BF, Ruokonen E, Magnusson-Borg K, Takala J. Nitrogen sparing effect of structured triglycerides containing both medium- and lung-chain fatty acids in critically ill patients: a double blind randomized controlled trial. Clin Nutr. 2001 ;20:43– 48.

68.

Mizock BA. Nutritional support in acute lung injury and acute respiratory distress syndrome. Nutr Clin Pract. 2001 ;16:319– 328.

69.

Rosmarin DK, Wardlaw GM, Mirtallo J. Hyperglycemia associated with high, continuous infusion rates of TPN dextrose. Nutr Clin Pract. 1996;11:151– 156.